Vetter announces major global expansion with investments in US and Germany

Vetter, a leading global contract development and manufacturing organization (CDMO), has unveiled significant expansion plans, which include relocating and enlarging its Development Services site in the United States and launching a new commercial production facility in Germany. These strategic moves underscore Vetter’s commitment to increasing its capacity and presence on both continents amid growing outsourcing demands in the injectable industry.

Expansion and Relocation in the United States

Vetter is set to move its Development Services from Skokie, Illinois, to a larger facility in Des Plaines, Illinois. This move, facilitated by the company’s strategic acquisition of the Des Plaines site a few years ago, aims to double the capacity of Vetter Development Services in the U.S. The expansion is driven by increasing customer demands and the need for additional space to accommodate future growth opportunities. Construction of new buildings for clinical manufacturing and related services at the Des Plaines site will commence over the next few years.

“Building on our existing investments, the new Des Plaines site will take Vetter Development Services to a new level, supporting our long-term business growth,” said Senator h.c. Udo J. Vetter, Chairman of the Advisory Board and member of the owner family.

Strategic Commercial Expansion in Saarland, Germany

In addition to its U.S. expansion, Vetter has received approval to establish an additional commercial production site in Saarlouis, Saarland. This decision aligns with the German Pharmaceutical Strategy and reflects the region’s burgeoning pharmaceutical infrastructure. Vetter’s extensive experience in managing production building projects in Germany will ensure cost and planning predictability. The Saarland government’s plans to develop a technology park on the site complement Vetter’s phased development plans for the 125-acre site, with an investment amounting to several hundred million Euros. The new facility is expected to commence pharmaceutical production by 2030 and aims to create up to 2,000 new local jobs.

“Germany, and Saarland in particular, provide the optimal conditions for expanding our commercial operations,” remarked Thomas Otto, Managing Director at Vetter. “This expansion not only enhances our service range but also reinforces our commitment to our customers and patients globally.”

Boosting Global Supply of Life-Saving Medications

These expansion efforts are part of Vetter’s comprehensive strategy to meet the increasing needs of the market for complex injectables. By boosting its development and manufacturing capabilities, Vetter aims to better serve the requirements of its clinical and commercial customers worldwide.

“The multiannual-long investments in our sites at Ravensburg and Langenargen are crucial, but the market demands more capacity,” added Peter Soelkner, Managing Director. “Our latest investments in Des Plaines and Germany are pivotal in our long-term strategy to support the global supply of life-saving medications.”

In conclusion, Vetter’s ambitious global expansion plans are set to significantly enhance its operational capabilities and capacity, ensuring the company remains at the forefront of the CDMO industry and continues to meet the growing demands of the pharmaceutical sector effectively.